Cancer Research Cancer Medicine 8 2010 Workshops
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 2869-2874, June 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burg, M. A.
Right arrow Articles by Stallcup, W. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burg, M. A.
Right arrow Articles by Stallcup, W. B.
[Cancer Research 59, 2869-2874, June 15, 1999]
© 1999 American Association for Cancer Research

Carcinogenesis

NG2 Proteoglycan-binding Peptides Target Tumor Neovasculature1

Michael A. Burg2, Renata Pasqualini, Wadih Arap, Erkki Ruoslahti and William B. Stallcup3

Cancer Research Center, The Burnham Institute, La Jolla, California 92037


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
NG2 is the rat homologue of the human melanoma proteoglycan, also known as the high molecular weight melanoma-associated antigen. This developmentally regulated membrane-spanning chondroitin sulfate proteoglycan is expressed primarily by glial, muscle, and cartilage progenitor cells. Upon maturation, these cell types down-regulate NG2 expression. In adult animals, the expression of NG2 is restricted to tumor cells and angiogenic tumor vasculature, making this proteoglycan a potential target for directing therapeutic agents to relevant sites of action. To this end, we have identified specific NG2-binding peptides by screening a phage-displayed random peptide library on purified NG2. Several rounds of biopanning on NG2 resulted in the specific enrichment of two phage-displayed decapeptides, TAASGVRSMH and LTLRWVGLMS. The binding of these phages to NG2 was inhibitable both by soluble NG2 and by glutathione S-transferase (GST) fusion proteins containing the cognate peptide sequences. In addition, direct binding between GST-TAASGVRSMH and GST-LTLRWVGLMS fusion proteins and NG2 was demonstrated in solid-phase binding assays. Interestingly, these NG2-binding fusion proteins cross-inhibited each other’s binding to NG2, suggesting that the two sequences bind to the same or overlapping sites on the proteoglycan. Upon injection into tumor-bearing mice, NG2-binding phages specifically homed to tumor vasculature in wild-type mice but did not localize to the tumor vasculature in NG2 knockout mice. The in vivo targeting capability of these sequences suggests that they can be used for tumor targeting.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Current anticancer strategies have been directed at the identification and characterization of molecules that are preferentially expressed by either tumor cells or cells of the angiogenic blood vessels associated with the tumor. Once identified, these molecules serve as potential targets for directing chemotherapeutic or immunotherapeutic agents to tumor cells and/or their associated vasculature (1, 2, 3, 4, 5, 6, 7) .

The rat proteoglycan NG2 (8) and its homologue, HMP4 (9) , are possible targets for anticancer therapy. NG2/HMP is widely expressed by several different tumors, including glioblastomas, chondrosarcomas, melanomas, and some leukemias (10, 11, 12, 13) . Numerous reports have shown that NG2/HMP expression increases the proliferative capacity of melanoma cells (14, 15, 16, 17) . Moreover, antibodies against NG2/HMP inhibit melanoma cell growth both in vitro (15) and in vivo (14, 15, 16) . Recently, we have shown that transfection of NG2 into NG2-negative B16F1 and B16F10 mouse melanoma cell lines increases both the proliferative capacity of these cells in vitro and tumor size in vivo (17) . NG2 expression also increased lung colonization for both B16F1 and B16F10 cells in experimental metastasis studies. Although the specific mechanism by which NG2 enhances the proliferative and metastatic properties of these cells is unclear, association of NG2 with known extracellular matrix ligands such as type VI collagen (18, 19, 20, 21) or cellular ligands such as CD44 and {alpha}4ß1 integrin (17 , 22) and its ability to enhance cellular responses to at least one growth factor, platelet-derived growth factor-AA (23 , 24) , appear to be important in these processes.

NG2/HMP is also widely expressed by angiogenic blood vessels. This is true not only for the expanding vasculature of normally developing tissues (23) but also for the neovasculature found in tumor stroma and in granulation tissue of healing wounds (12 , 25 , 26) . In contrast, NG2/HMP is not detectable in normal quiescent vasculature. Immunohistochemical studies have suggested that NG2/HMP expression in neovasculature is limited to the neovascular pericytes (25 , 26) . However, NG2/HMP expression by endothelial cells in developing brain capillaries has also been reported (12 , 23) . Pericytes are intimately associated with endothelial cells in developing vasculature (27) and are thought to affect angiogenesis by regulating endothelial cell proliferation, directing microvessel outgrowth, and stabilizing capillary walls (27, 28, 29, 30) .

Because of the selective expression of NG2/HMP in tumor cells and tumor vasculature, several groups have chosen this molecule as a target for immunotherapy of cancer. An anti-NG2/HMP mAb-doxorubicin conjugate was shown to suppress malignant melanoma growth in a nude mouse model (31) . Additionally, anti-NG2/HMP mAb-toxin and 131I-radiolabeled conjugates have been shown to have some therapeutic value for patients with malignant melanoma (32 , 33) . However, these trials have not been as successful as one might have hoped. In general, antibody-based therapies are often found to have limitations, mostly due to poor tissue penetration and unwanted immune responses (3 , 6 , 34, 35, 36, 37) . The alternative approach of using small peptides capable of targeting cells within tumor vasculature or stroma may alleviate many of the problems associated with antibody-based targeting strategies (2 , 7 , 37) .

Phage display of random peptide libraries has proven to be successful in the isolation of peptides capable of binding to integrins (38, 39, 40) , growth factor receptors (41) , and other tumor cell-associated proteins (42, 43, 44) . Moreover, in vivo phage targeting has allowed us to identify several peptides that home to vasculature of specific organs as well as to tumor neovasculature (45, 46, 47) . Here, we have used phage display to isolate peptides that bind to the NG2 proteoglycan and home to NG2-expressing tumor neovasculature.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Materials.
B16F10 mouse melanoma cells were obtained from the Division of Cancer Treatment Tumor Bank, National Cancer Institute-Frederick Cancer Research Facility (Frederick, MD). Rat antimouse CD31 antibodies were obtained from PharMingen (La Jolla, CA). Rabbit antibodies against NG2 have been described previously (23 , 24) .

Fuse5 vector and K91 bacterial strain were a gift from G. Smith (University of Missouri-Columbia, Ref. 48 ). Construction of the random linear decapeptide phage library has been described (39) . The library titer was ~1013 TU/ml.

Isolation of NG2-binding Phages.
A recombinant fragment of rat NG2 consisting of the NH2-terminal two-thirds of the extracellular domain (NG2EC{Delta}3) was purified from transfected human embryonic kidney 293 cells as described (21) . Recombinant NG2{Delta}3 diluted in PBS (2 µg of NG2 per well) was coated onto microtiter wells overnight at 4°C. Wells were blocked with 2% PBS-BSA for 1 h at room temperature. For biopanning, phages (1 x 1011 TU) from a linear decapeptide phage library diluted in 2% BSA were added to proteoglycan-coated wells and incubated for 2 h at room temperature. Wells were washed with PBS containing 0.1% Tween 20 to remove unbound phages. Bound phages were recovered by direct infection of wells with exponentially growing K91kan bacteria, followed by phage amplification overnight at 37°C. Amplified phages were then subjected to four subsequent rounds of selection on NG2-coated wells. Phage binding was quantified by counting colonies from aliquots of phage-infected bacteria removed from NG2-coated wells. Phages were sequenced from randomly selected clones as described (39) .

Binding of individual phage clones or an aliquot of unselected phage library control to NG2{Delta}3 or BSA-coated control wells was performed as described above using 1 x 109 input phages per well. For competition studies, phage incubations were performed in the presence of increasing concentrations of soluble NG2{Delta}3 or GST fusion proteins. Soluble GST alone was used as a control in these competition experiments.

Solid-phase Binding Assays.
GST fusion proteins containing the decapeptide inserts were constructed as described previously (47) and dissolved in PBS. Briefly, peptide inserts were PCR-amplified from the phages using specific M13 primers. PCR products were then digested with BamHI and EcoRI and inserted into the pGEX2TK vector. Fusion proteins were produced and purified according to manufacturer’s instructions (Pharmacia, Buckinghamshire, England).

Solid-phase assays were performed as described previously (19) . Briefly, GST fusion proteins or GST alone (2 µg/well) were coated onto microtiter wells overnight at 4°C. Wells were blocked with 2% BSA-PBS and incubated with soluble NG2{Delta}3 (1 µg/well) for 2 h at room temperature. After washing, wells were incubated with an anti-NG2 polyclonal antibody followed by washing and incubation with an 125I-labeled goat antirabbit IgG. After a final washing, bound radioactivity was determined using a gamma counter. For competition studies, soluble NG2{Delta}3 was preincubated for 15 min with increasing concentrations of soluble GST fusion proteins prior to incubation on GST fusion protein-coated wells. Preincubation with GST alone served as a control in these competition experiments.

In Vivo Phage Targeting.
In vivo phage targeting was performed on 4–6-week-old NG2 knockout mice and control F1 wild-type mice. Generation and characterization of these mice has been previously described (49) . For tumor generation, B16F10 mouse melanoma cells were harvested from subconfluent cultures using nonenzymatic cell dissociation buffer (Life Technologies, Inc., Gaithersburg, MD). Cells (1 x 106 cells in 0.2 ml of DMEM) were injected s.c. into the mouse right flank. Tumors were monitored between 10 and 20 days postinjection, and animals bearing tumors of ~1–2 cm in diameter were selected for phage targeting.

Tumor targeting using phages was performed as described previously (46) . Briefly, phages (1 x 109–1 x 1010) were injected i.v. (lateral tail vein) into anesthetized (0.017 ml per g of Avertin) mice and allowed to circulate for 5 min. Mice were then perfused through the heart with 5 ml of DMEM. Tumors and brains were removed and weighed. Tissues were homogenized in DMEM containing protease inhibitors (45) , and phages were rescued and quantified from these tissues as described (45 , 46) .

Immunohistochemistry.
For immunohistochemistry, B16F10 tumors were grown in NG2 knockout and F1 control mice as described above. Tumors were removed and fresh-frozen, and 25-µm sections were cut on a cryostat. Tumor vascularization was visualized using a mixture of a rat antimouse CD31 mAb (Pharmacia) and anti-NG2 polyclonal antibodies. Secondary staining was performed with FITC-conjugated antirabbit immunoglobulin and rhodamine isothiocyanate-conjugated antirat immunoglobulin antibodies (Biosource International, Camarillo, CA). Confocal images were obtained using a Zeiss LSM 410 laser scanning confocal microscope (Carl Zeiss, Thornwood, NY).


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Isolation of NG2-binding Phages.
To identify peptide motifs capable of interacting with NG2, we coated recombinant NG2 fragments consisting of the NH2-terminal two-thirds of the extracellular domain of the proteoglycan (NG2{Delta}3) onto microtiter wells and used them to select phage clones from a random decapeptide phage display library. Bound phages were isolated and used for successive rounds of panning on the proteoglycan. Random clones were sequenced from rounds II–V. Sequence analysis from the final three rounds of panning (Table 1)Citation indicates the specific enrichment of two decapeptide sequences, TAASGVRSMH and LTLRWVGLMS. These sequences first appeared in round II and III and became the exclusive motifs bound to NG2 in the subsequent rounds of selection.


View this table:
[in this window]
[in a new window]

  		Table 1 Selection of NG2-binding phage from a linear decapeptide phage librarya

 
Binding Characteristics of the TAASGVRSMH and LTLRWVGLMS Phages.
Phages displaying TAASGVRSMH or LTLRWVGLMS were tested individually for their ability to bind to NG2{Delta}3-coated wells. The results showed that both phages specifically bind to the proteoglycan. An equivalent number of control phages from the unselected decapeptide phage library (Fig. 1)Citation or phages containing no peptide inserts (data not shown) showed negligible binding to NG2. Moreover, binding of the TAASGVRSMH and LTLRWVGLMS phages to BSA was minimal compared to their binding to the proteoglycan.



View larger version (23K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Phage attachment assay. Purified TAASGVRSMH (TAA) and LTLRWVGLMS (LTL) phages or an unselected library mix (unamplified decapeptide library) were incubated in NG2{Delta}3-coated ({blacksquare}) or BSA-coated () microtiter wells and bound phages were quantified as described in "Materials and Methods." Results are representative of three independent experiments. Columns, means from triplicate platings; bars, SE. All differences are statistically highly significant, as assessed by the Student’s t test (P < 0.01).

 
To confirm the specificity of these interactions, we incubated both species of NG2-binding phages with increasing concentrations of soluble recombinant NG2{Delta}3 prior to incubation with NG2{Delta}3-coated wells. The results show a dose-dependent inhibition of binding of both phage populations to the NG2-coated substratum (Fig. 2)Citation . As a control, preincubation of the two phage species with GST did not inhibit binding to NG2{Delta}3. In addition, the low level of binding of unselected phages to NG2{Delta}3 (as illustrated in Fig. 1Citation ) was not affected by incubation with either soluble NG2{Delta}3 or GST, confirming the nonspecific nature of this binding (data not shown).



View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Inhibition of phage binding by soluble NG2. Purified TAASGVRSMH phage ({circ} and •) and LTLRWVGLMS phage ({square} and {blacksquare}) were incubated in NG2{Delta}3-coated wells in the presence of the indicated concentrations of soluble NG2{Delta}3 (• and {blacksquare}) or soluble GST ({circ} and {square}). Bound phages were quantified as described above. Results are representative of three independent experiments. Data points, means from triplicate platings of duplicate wells; bars, SE.

 
Inhibition of Phage Binding with Cognate Sequences.
GST fusion proteins containing the two NG2-binding motifs were constructed and tested for their ability to inhibit binding of phages to NG2{Delta}3-coated wells. When TAASGVRSMH phages were allowed to bind to NG2{Delta}3 coated wells in the presence of increasing concentrations of the cognate fusion protein, a dose-dependent decrease in binding was observed (Fig. 3A)Citation . Interestingly, the binding of these phages to NG2{Delta}3 was also inhibited by increasing concentrations of GST-LTLRWVGLMS. In contrast, incubation of the phages with a control GST protein without a peptide insert did not significantly inhibit binding.



View larger version (16K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Inhibition of phage binding by cognate sequences. Purified phages were incubated in NG2{Delta}3-coated wells in the presence of the indicated concentrations of GST-TAASGVRSMH fusion protein ({circ}), GST-LTLRWVGLMS fusion protein ({blacksquare}), or GST alone (•), and phage binding was quantified. Results are representative of three independent experiments. Data points, means from triplicate platings of duplicate wells; bars, SE. *, considered highly significant by the Student’s t test (P < 0.01). A, binding of TAASGVRSMH phage. B, binding of LTLRWVGLMS phage.

 
A similar result was obtained when the binding of LTLRWVGLMS phage was tested in the presence of increasing concentrations of GST fusion proteins. Both fusion proteins inhibited the binding of this phage species to NG2{Delta}3, whereas the control GST protein had no significant effect on the binding (Fig. 3B)Citation .

Solid-phase Binding of GST Fusion Proteins to NG2.
The ability of soluble NG2{Delta}3 to bind to GST, GST-TAASGVRSMH, and GST- LTLRWVGLMS was tested by using a solid-phase assay. The results indicate that the soluble proteoglycan binds much more effectively to the immobilized fusion proteins than to GST alone (Fig. 4)Citation . In addition, preincubation of NG2{Delta}3 with increasing concentrations of GST-TAASGVRSMH resulted in a dose-dependent decrease in binding of the proteoglycan to wells coated with this same fusion protein (Fig. 4B)Citation . Preincubation of NG2{Delta}3 with increasing concentrations of GST-LTLRWVGLMS also inhibited binding of the proteoglycan to wells coated with GST-TAASGVRSMH. These results reinforce the notion that the two peptides bind to similar sites on NG2. Both of the soluble fusion proteins also inhibited the binding of NG2{Delta}3 to wells coated with GST-LTLRWVGLMS (Fig. 4C)Citation . In both cases, preincubation of the proteoglycan with soluble GST failed to give significant inhibition of binding to the GST fusion proteins (Fig. 4, B and C)Citation . In addition, the level of nonspecific binding of NG2{Delta}3 to GST alone was not further reduced by preincubation with GST or GST fusion proteins (Fig. 4A)Citation .



View larger version (52K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. Binding of NG2 to immobilized fusion proteins. Purified NG2{Delta}3 was incubated in GST or GST fusion protein-coated wells in the absence of inhibitor ({blacksquare}) or after preincubation with 50 µg of soluble GST (), GST-TAASGVRSMH (), or GST-LTLRWVGLMS ({square}). Binding of NG2{Delta}3 was determined as described in "Materials and Methods." Results are representative of three independent experiments. Columns, means from triplicate wells; bars, SE. *, considered significant by Student’s t test (P < 0.05); **, considered highly significant by Student’s t test (P < 0.01). A, binding to GST-coated wells (GST). B, binding to GST-TAASGVRSMH-coated wells (GST-TAA). C, binding to GST-LTLRWVGLMS-coated wells (GST-LTL).

 
Tumor Targeting in Vivo Using NG2-binding Phages.
We were interested in determining whether NG2-binding phages were capable of targeting NG2 within tumor vasculature. We compared the ability of NG2-binding phages to home to the vasculature of B16 melanoma xenografts growing in either wild-type or NG2-null mice. When an equivalent number of NG2-binding phages were injected i.v. into the two lines of tumor-bearing mice, both TAASGVRSMH and LTLRWVGLMS phages were found to home specifically to tumors of NG2-expressing wild-type mice. In contrast, there was much less homing to tumors established in NG2 null mice (Fig. 5A)Citation . In addition, control phages did not show selective accumulation to the tumors established in either wild-type or NG2 knockout mice. In a separate experiment, tumor targeting phage previously shown to bind to {alpha}v integrins (46) exhibited equivalent abilities to target tumors in wild-type and NG2-null mice (Fig. 5B)Citation . This result indicates that the homing of NG2-binding phages to tumors in wild-type mice is mediated by NG2 expression and is not due to other differences between tumor vasculature of wild-type and NG2-null mice.



View larger version (32K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 5. Homing of phages to tumor vasculature. Tumor (B16F10)-bearing NG2-null () or F1 wild-type ({blacksquare}) mice were injected i.v. via the tail vein with 1010 TU of purified RGD-4C, TAASGVRSMH, LTLRWVGLMS, or unselected library mix (unamplified decapeptide library) phages. Five min after injection, mice were perfused, and phages were recovered from tumors and from brain as described in "Materials and Methods." Phage yields were quantified as the number of TU recovered per g of tissue. As a measure of specific homing to tumors, results in the figure are expressed as a ratio of tumor homing phages to brain homing phages. Results are representative of three independent experiments. Columns, means from triplicate platings; bars, SE. All differences in A are considered highly significant by Student’s t test (P < 0.01). A, homing of NG2-binding phages. B, homing of RGD-4C phages.

 
Immunohistochemical examination of the tumor vasculature in wild-type mice showed NG2 expression was limited to vascular pericytes, which were abluminally associated with CD31-positive endothelial cells (Fig. 6, A–C)Citation . NG2-knockout mice exhibited no NG2 immunoreactivity but showed normal CD31-positive endothelial cell staining (Fig. 6, D–F)Citation . No other major difference between vasculature of B16 tumors grown in wild-type and NG2 knockout mice was observed.



View larger version (25K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 6. Immunohistochemical analysis of tumor vasculature in NG2-knockout and wild-type mice. Cryostat sections prepared from B16F10 tumors isolated from NG2-knockout (D–F) or F1 wild-type (A–C) mice were double labeled with a polyclonal antiserum directed against NG2 (A and D) and a rat mAb against CD31 (B and E). Sections were then stained with fluorescein-conjugated goat antirabbit and rhodamine-conjugated goat antirat secondary antibodies, and confocal images through a single section were obtained. Superimposition of confocal images reveals NG2 expression on pericytic cells abluminally apposed to CD31-positive endothelial cells in wild-type mice (C). No NG2 expression was observed in the tumor vasculature of the NG2 knockout mouse (D and F). Note that the B16 cells themselves are NG2 and CD31 negative and do not contribute to the staining pattern. Scale bar (D), 10 µm.

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Here, we have described the use of phage display to identify two novel peptide ligands for the NG2 proteoglycan. These decapeptides compete with one another for binding to NG2, suggesting that they recognize the same or overlapping sites on the proteoglycan. The two sequences are clearly different but may act as mimotopes of each other on the basis of small areas of similarity (VR versus LR, SM versus MS, and ASG versus LTL). Database searches revealed no significant similarities between the two decapeptide sequences and known ligands for the proteoglycan (17 , 19 , 21) . They, therefore, represent either novel ligands or mimotopes of sequences present in previously characterized ligands.

Both of the NG2-binding sequences are able to direct the homing of peptide-bearing phages to the NG2-positive neovasculature of melanoma xenografts in mice. Significantly, this tumor homing is greatly reduced in NG2-null mice, illustrating the importance of NG2 as the target molecule. In wild-type mice, we were able to localize NG2 expression to pericytes in the angiogenic vasculature of the xenografts. This agrees with earlier reports of NG2 localization in tumor vasculature (25 , 26) . Because the phages are relatively large particles and not likely to be able to penetrate an intact endothelial layer in the short time we used for the homing, our results show that pericytes in tumor vessels are accessible to circulating probes. The reason for this may be that tumor vessels are "leaky" (50, 51, 52) . The localization and accessibility of NG2 on pericytes suggest the potential use of NG2-homing sequences for targeting delivery of therapeutic agents to tumors. Several reports have suggested that pericytes play an important role in controlling endothelial cell proliferation and stabilization during angiogenesis (27, 28, 29, 30) . Thus, anticancer strategies based on the targeting of pericytes in angiogenic vasculature may complement approaches based on endothelial cell targeting. Because NG2 is also expressed by the tumor cells themselves in many types of tumors (10, 11, 12, 13) , the NG2-binding peptides could deliver therapeutics to the tumor cells themselves in addition to targeting tumor vasculature. The small peptides may prove superior to antibodies in terms of penetration into tumors. Future studies will evaluate the relative merits of peptides and antibodies as targeting vectors for NG2.

Specific targeting of tumor vasculature or combined targeting of vasculature and tumor cells offers several advantages over therapies that are strictly tumor-directed. Probes that target tumor cells themselves are limited by both the heterogeneous expression of tumor antigens within the tumor, as well as by the high rate of tumor cell mutation (1 , 2 , 6 , 53) . In contrast, cells that comprise tumor vasculature are nonmalignant, relatively homogenous cell populations. The development of resistance to chemotherapy resulting from the high rate of tumor cell mutations is also circumvented by targeting normal cells of the tumor vasculature (54, 55, 56) .

Finally, the NG2-binding peptides may allow us to identify additional physiological ligands for NG2. Such insights may help elucidate the role of NG2 during development and in pathological conditions. NG2 expression has been found to affect cellular responses to platelet-derived growth factor-AA and cellular interactions with extracellular matrix components (18 , 20 , 23 , 24) . In addition, the expression of NG2 increases the malignant potential of tumor cells (17) . These findings suggest that NG2 may play a functional role in angiogenesis and tumor development. The peptides we have isolated in this work may prove to be useful probes for analyzing these functions.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by NIH Grants R01CA74238 (to E. R.), R01NS21990, and R01NS32767 (to W. B. S.) and by Cancer Center Support Grant CA30199 from the National Cancer Institute. M. A. B. is supported by NIH Fellowship F32CA72220 and W. A. is the recipient of a CaPCURE award. Back

2 Present address: Selective Genetics, Inc., 11035 Roselle Street, San Diego, CA 92121. Back

3 To whom requests for reprints should be addressed, at Cancer Research Center, The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037. Phone: (619) 455-6480 ext. 3220; Fax: (619) 646-3197; E-mail: stallcup{at}burnham-inst.org Back

4 The abbreviations used are: HMP, human melanoma proteoglycan; mAb, monoclonal antibody; TU, transducing unit(s); GST, glutathione S-transferase. Back

Received 12/22/98. Accepted 4/16/99.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1: 27-31, 1995.[Medline]
  2. Folkman J. Antiangiogenic therapy Ed. 5 DeVita V. T. Hellman S. Rosenberg S. A. eds. . Cancer: Principles and Practice of Oncology, : 3075-3085, Lippincott-Raven Philadelphia 1997.
  3. Baillie C. T., Winslet M. C., Bradley N. J. Tumour vasculature: a potential therapeutic target. Br. J. Cancer, 72: 257-267, 1995.[Medline]
  4. Rak J. W., St. Croix B. D., Kerbel R. S. Consequences of angiogenesis for tumor progression, metastasis and cancer. Anticancer Drugs, 6: 3-18, 1995.[Medline]
  5. Derbyshire E. J., Thorpe P. E. Targeting the tumour endothelium using specific antibodies Bicknell R. Lewis C. E. Ferrara N. eds. . Tumor Angiogenesis, : 343-356, 1998.
  6. Burrows F. J., Thorpe P. E. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc. Natl. Acad. Sci. USA, 90: 8996-9000, 1993.[Abstract/Free Full Text]
  7. Arap W., Pasqualini R., Ruoslahti E. Chemotherapy targeted to tumor vasculature. Curr. Opin. Oncol., 10: 560-565, 1998.[Medline]
  8. Nishiyama A., Dahlin K. J., Prince J. T., Johnstone S. R., Stallcup W. B. The primary structure of NG2, a novel membrane-spanning proteoglycan. J. Cell Biol., 114: 359-371, 1991.[Abstract/Free Full Text]
  9. Pluschke G., Vanek M., Evans A., Dittmar T., Schmid P., Itin P., Filardo E., Reisfeld R. Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan. Proc. Natl. Acad. Sci. USA, 93: 9710-9715, 1996.[Abstract/Free Full Text]
  10. Behm F. G., Smith F. O., Raimondi S. C., Pui C-H., Bernstein I. D. Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;13) and MLL gene rearragements. Blood, 87: 1134-1139, 1996.[Abstract/Free Full Text]
  11. Real F. X., Houghton A. N., Albino, Cordon-Cardo C., Melamed M. R., Oettgen H. F., Old L. J. Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity, analysis, and comparison of antigen expression in cultured cells and tissues. Cancer Res., 45: 4401-4411, 1985.[Abstract/Free Full Text]
  12. Schrappe M., Klier F. G., Spiro R. C., Waltz T. A., Reisfeld R. A., Gladson C. L. Correlation of chondroitin sulfate proteoglycan expression on proliferating brain capillary endothelial cells with the malignant phenotype of astroglial cells. Cancer Res., 51: 4986-4993, 1991.[Abstract/Free Full Text]
  13. Leger O., Johnson-Leger C., Jackson E., Coles B., Dean C. The chondroitin sulfate proteoglycan NG2 is a tumor specific antigen on the chemically induced rat chondrosarcoma HSN. Int. J. Cancer, 58: 700-705, 1994.[Medline]
  14. Bumol T. F., Wang Q. C., Reisfeld R. A., Kaplan N. O. Monoclonal antibody and an antibody-toxin conjugate to a cell surface proteoglycan of melanoma cells suppress in vivo tumor growth. Proc. Natl. Acad. Sci. USA, 80: 529-533, 1983.[Abstract/Free Full Text]
  15. Harper J. R., Reisfeld R. A. Inhibition of anchorage-independent growth of human melanoma cells by a monoclonal antibody to a chondroitin sulfate proteoglycan. J. Natl. Cancer Inst. (Bethesda), 71: 259-263, 1983.
  16. Harper J. R., Reisfeld R. A. Cell-associated proteoglycans in human malignant melanoma Wight T. Mecham R. eds. . Biology of Proteoglycans, : 345-366, Academic Press New York 1987.
  17. Burg M. A., Grako K. A., Stallcup W. B. Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cells. J. Cell. Physiol., 177: 299-312, 1998.[Medline]
  18. Nishiyama A., Stallcup W. B. Expression of NG2 proteoglycan causes retention of type VI collagen on the cell surface. Mol. Biol. Cell, 4: 1097-1108, 1993.[Abstract]
  19. Burg M. A., Tillet E., Timpl R., Stallcup W. B. Binding of the NG2 proteoglycan to type VI collagen and other extracellular matrix molecules. J. Biol. Chem., 271: 26110-26116, 1996.[Abstract/Free Full Text]
  20. Burg M. A., Nishiyama A., Stallcup W. B. A central segment of the NG2 proteoglycan is critical for the ability of glioma cells to bind and migrate toward type VI collagen. Exp. Cell Res., 235: 254-264, 1997.[Medline]
  21. Tillet E., Ruggiero F., Nishiyama A., Stallcup W. B. The membrane-spanning proteoglycan NG2 binds to collagen V and VI through the central non-helical portion of the ectodomain. J. Biol. Chem., 272: 10769-10776, 1997.[Abstract/Free Full Text]
  22. Iida J., Meijne A., Spiro R., Roos E., Furcht L., McCarthy J. Spreading and focal contact formation of human melanoma cells in response to the stimulation of both NG2 and {alpha}4ß1 integrin. Cancer Res., 55: 2177-2185, 1995.[Abstract/Free Full Text]
  23. Grako K., Stallcup W. B. Participation of the NG2 proteoglycan in rat aortic smooth muscle cell responses to platelet-derived growth factor. Exp. Cell Res., 221: 231-240, 1995.[Medline]
  24. Nishiyama A., Lin X-H., Giese N., Heldin C-H., Stallcup W. B. Interaction between NG2 proteoglycan and PDGF {alpha} receptor is required for optimal response to PDGF. J. Neurosci. Res., 43: 315-330, 1996.[Medline]
  25. Schlingemann R. O., Rietveld F. J. R., de Waal R. M. W., Ferrone S., Ruiter D. J. Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds. Am. J. Pathol., 136: 1393-1405, 1990.[Abstract]
  26. Schlingemann R. O., Rietveld F. J., Kwaspen F., van de Kerkhof P. C., de Waal R. M., Ruiter D. J. Differential expression of markers for endothelial cells, pericytes, and basal lamina in the microvasculature of tumors and granulation tissue. Am. J. Pathol., 138: 1335-1347, 1991.[Abstract]
  27. Sims D. E. The pericyte: a review. Tissue Cell, 18: 153-174, 1986.[Medline]
  28. Hirschi K. K., D’Amore P. A. Control of angiogenesis by the pericyte: molecular mechanisms and significance Goldberg I. D. Rosen E. M. eds. . Regulation of Angiogenesis, : 419-428, Birkhauser Verlag Basel, Switzerland 1997.
  29. Lindahl P., Betsholtz C. Not all myofibroblasts are alike: revisiting the role of PDGF-A and PDGF-B using PDGF-targeted mice. Curr. Opin. Nephrol. Hypertens., 7: 21-26, 1998.[Medline]
  30. Lindahl P., Johansson B. R., Leveen P., Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science (Washington DC), 277: 242-245, 1997.[Abstract/Free Full Text]
  31. Yang H. M., Reisfeld R. A. Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice. Proc. Natl. Acad. Sci. USA, 85: 1189-1193, 1988.[Abstract/Free Full Text]
  32. Spitler L. E., del Rio M., Khentigan A., Wedel N. I., Brophy N. A., Miller L. L., Harkonen W. S., Rosendorf L. L., Lee H. M., Mischak R. P., Kawahata R. T., Stoudemire J. B., Fradkin L. B., Bautista E. E., Scannon P. J. Therapy of patients with malignant melanoma using a monoclonal anti-melanoma antibody-ricin immunotoxin. Cancer Res., 47: 1717-1723, 1987.[Abstract/Free Full Text]
  33. Bigner D. D., Brown M., Coleman R. E., Friedman A. H., Friedman H. S., McLendon R. E, Bigner S. H., Zhao X-G., Wikstrand C. J., Pegram C. N., Kerby T., Zalutsky M. R. Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin sulfate proteoglycan Mel-14F(ab')2: a preliminary report. J. Neuro-Oncol., 24: 109-122, 1995.[Medline]
  34. Shockley T. R., Lin K., Nagy J. A., Tompkins R. G., Dvorak H. F., Yarmush M. L. Penetration of tumor tissue by antibodies and other immunoproteins. Ann. N. Y. Acad. Sci., 618: 367-382, 1991.[Medline]
  35. Dvorak H. F., Nagy J. A., Dvorak A. M. Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Cancer Cells, 3: 77-85, 1991.[Medline]
  36. Molema G., de Leij L. F., Meijer D. K. Tumor vascular endothelium: barrier or target in tumor directed drug delivery and immunotherapy. Pharm. Res., 14: 2-10, 1997.[Medline]
  37. Jain R. K. Delivery of molecular and cellular medicine to solid tumors. Microcirculation, 4: 3-23, 1997.
  38. Koivunen E., Wang B., Ruoslahti E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. BioTechnology, 13: 265-270, 1995.[Medline]
  39. Koivunen, E., Restel, B., Rajotte, D., Lahdenranta, J., Hagedorn, M., Arap, W., and Pasqualini, R. Integrin-binding peptides from phage display peptide libraries. Integrin protocols. Methods Mol. Biol., in press, 1999.
  40. Murayama O., Nishida H., Sekiguchi K. Novel peptide ligands for integrin {alpha}6ß1 selected from a phage display library. J. Biochem., 120: 445-451, 1996.[Abstract/Free Full Text]
  41. Yanofsky S. D., Baldwin D. N., Butler J. H., Holden F. R., Jacobs J. W., Balasubramanian P., Chinn J. P., Cwirla S. E., Peters-Bhatt E., Whitehorn E. A., Tate E. H., Adeson A., Bowlin T. L., Dower W. J., Barret R. W. High affinity type I interleukin 1 receptor antagonists discovered by screening recombinant peptide libraries. Proc. Natl. Acad. Sci. USA, 93: 7381-7386, 1996.[Abstract/Free Full Text]
  42. Popkov M., Lussier I., Medvedkine V., Esteve P-E., Alakhov V., Mandeville R. Multidrug-resistance drug-binding peptides generated by using a phage display library. Eur. J. Biochem., 251: 155-163, 1998.[Medline]
  43. Pennington M. E., Lam K. S., Cress A. E. The use of a combinatorial library method to isolate human tumor cell adhesion peptides. Mol. Divers., 2: 19-28, 1996.[Medline]
  44. Goodson R. J., Doyle D. V., Kaufman S. E., Rosenberg S. High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc. Natl. Acad. Sci. USA, 91: 7129-7133, 1994.[Abstract/Free Full Text]
  45. Pasqualini R., Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature (Lond.), 380: 364-366, 1996.[Medline]
  46. Pasqualini R., Koivunen E., Ruoslahti E. {alpha}v integrins as receptors for tumor targeting by circulating ligands. Nat. Biotechnol., 15: 542-546, 1997.[Medline]
  47. Rajotte D., Arap W., Hagedorn M., Koivunen E., Pasqualini R., Ruoslahti E. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J. Clin. Invest., 102: 430-437, 1998.[Medline]
  48. Smith G. P., Scott J. K. Libraries of peptides and proteins displayed in filamentous phage. Methods Enzymol., 21: 228-257, 1993.
  49. Grako K. A., Ochiya T. A., Barritt D., Nishiyama A., Stallcup W. B. PDGF {alpha}-receptor is unresponsive to PDGF-AA in aortic smooth muscle cells from the NG2 knockout mouse. J. Cell Sci., 112: 905-915, 1999.[Abstract]
  50. Blood C. H., Zetter B. R. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim. Biophys. Acta, 1032: 89-118, 1990.[Medline]
  51. Nagy J. A., Brown L. F., Senger D. R., Lanir N., Van de Water L., Dvorak A. M., Dvorak H. F. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim. Biophys. Acta, 948: 305-326, 1989.[Medline]
  52. Dvorak H. F., Nagy J. A., Dvorak J. T., Dvorak A. M. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am. J. Pathol., 133: 95-109, 1989.[Abstract]
  53. Nowell P. C. The clonal evolution of tumor cell populations. Science (Washington DC), 194: 23-28, 1976.[Abstract/Free Full Text]
  54. Kerbel R. S. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. BioEssays, 13: 31-36, 1991.[Medline]
  55. Kerbel R. S. A cancer therapy resistant to resistance. Nature (Lond.), 390: 335-336, 1997.[Medline]
  56. Boehm T., Folkman J., Browder T., O’Reilly M. S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (Lond.), 390: 404-407, 1997.[Medline]



This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
R. J. Passarella, L. Zhou, J. G. Phillips, H. Wu, D. E. Hallahan, and R. Diaz
Recombinant Peptides as Biomarkers for Tumor Response to Molecular Targeted Therapy
Clin. Cancer Res., October 15, 2009; 15(20): 6421 - 6429.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
J. Lahdenranta, R. L. Sidman, R. Pasqualini, and W. Arap
Treatment of hypoxia-induced retinopathy with targeted proapoptotic peptidomimetic in a mouse model of disease
FASEB J, October 1, 2007; 21(12): 3272 - 3278.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. L. Arbiser, T. Kau, M. Konar, K. Narra, R. Ramchandran, S. A. Summers, C. J. Vlahos, K. Ye, B. N. Perry, W. Matter, et al.
Solenopsin, the alkaloidal component of the fire ant (Solenopsis invicta), is a naturally occurring inhibitor of phosphatidylinositol-3-kinase signaling and angiogenesis
Blood, January 15, 2007; 109(2): 560 - 565.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
Y. Oh, I. Mohiuddin, Y. Sun, J. B. Putnam Jr, W. K. Hong, W. Arap, and R. Pasqualini
Phenotypic Diversity of the Lung Vasculature in Experimental Models of Metastases
Chest, December 1, 2005; 128(6_suppl): 596S - 600S.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
Y. Oh, I. Mohiuddin, Y. Sun, J. B. Putnam Jr, W. K. Hong, W. Arap, and R. Pasqualini
Phenotypic Diversity of the Lung Vasculature in Experimental Models of Metastases
Chest, December 1, 2005; 128(6_suppl): 596S - 600S.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Kessler, R. Bieker, T. Padro, C. Schwoppe, T. Persigehl, C. Bremer, M. Kreuter, W. E. Berdel, and R. M. Mesters
Inhibition of Tumor Growth by RGD Peptide-Directed Delivery of Truncated Tissue Factor to the Tumor Vasculature
Clin. Cancer Res., September 1, 2005; 11(17): 6317 - 6324.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Zitzmann, W. Mier, A. Schad, R. Kinscherf, V. Askoxylakis, S. Kramer, A. Altmann, M. Eisenhut, and U. Haberkorn
A New Prostate Carcinoma Binding Peptide (DUP-1) for Tumor Imaging and Therapy
Clin. Cancer Res., January 1, 2005; 11(1): 139 - 146.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
S. Hughes and T. Chan-Ling
Characterization of Smooth Muscle Cell and Pericyte Differentiation in the Rat Retina In Vivo
Invest. Ophthalmol. Vis. Sci., August 1, 2004; 45(8): 2795 - 2806.
[Abstract] [Full Text] [PDF]

Home page
 Br J OphthalmolHome page
Y Li, M C Madigan, K Lai, R M Conway, F A Billson, R Crouch, and B J Allen
Human uveal melanoma expresses NG2 immunoreactivity
Br J Ophthalmol, May 1, 2003; 87(5): 629 - 632.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
T. Nakamura, K. Sato, and H. Hamada
Reduction of Natural Adenovirus Tropism to the Liver by both Ablation of Fiber-Coxsackievirus and Adenovirus Receptor Interaction and Use of Replaceable Short Fiber
J. Virol., February 15, 2003; 77(4): 2512 - 2521.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Sevigny, C. Sundberg, N. Braun, O. Guckelberger, E. Csizmadia, I. Qawi, M. Imai, H. Zimmermann, and S. C. Robson
Differential catalytic properties and vascular topography of murine nucleoside triphosphate diphosphohydrolase 1 (NTPDase1) and NTPDase2 have implications for thromboregulation
Blood, April 15, 2002; 99(8): 2801 - 2809.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
W. B. Stallcup and K. Dahlin-Huppe
Chondroitin sulfate and cytoplasmic domain-dependent membrane targeting of the NG2 proteoglycan promotes retraction fiber formation and cell polarization
J. Cell Sci., March 8, 2002; 114(12): 2315 - 2325.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Essler and E. Ruoslahti
Molecular specialization of breast vasculature: A breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature
PNAS, February 19, 2002; 99(4): 2252 - 2257.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
C. Sundberg, J. A. Nagy, L. F. Brown, D. Feng, I. A. Eckelhoefer, E. J. Manseau, A. M. Dvorak, and H. F. Dvorak
Glomeruloid Microvascular Proliferation Follows Adenoviral Vascular Permeability Factor/Vascular Endothelial Growth Factor-164 Gene Delivery
Am. J. Pathol., March 1, 2001; 158(3): 1145 - 1160.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Pasqualini, E. Koivunen, R. Kain, J. Lahdenranta, M. Sakamoto, A. Stryhn, R. A. Ashmun, L. H. Shapiro, W. Arap, and E. Ruoslahti
Aminopeptidase N Is a Receptor for Tumor-homing Peptides and a Target for Inhibiting Angiogenesis
Cancer Res., February 1, 2000; 60(3): 722 - 727.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
L. Goretzki, C. R. Lombardo, and W. B. Stallcup
Binding of the NG2 Proteoglycan to Kringle Domains Modulates the Functional Properties of Angiostatin and Plasmin(ogen)
J. Biol. Chem., September 8, 2000; 275(37): 28625 - 28633.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burg, M. A.
Right arrow Articles by Stallcup, W. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burg, M. A.
Right arrow Articles by Stallcup, W. B.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online